
Ferran Fece de la Cruz
@FerranFeceCruz
Followers
584
Following
19K
Media
63
Statuses
1K
Cancer researcher, Catalan, Instructor at @MGHCancerCenter & @harvardmed #CorcoranLab PhD in Malignant Diseases at @CeMM_News (Vienna) & @Ludwig_Cancer (Oxford)
Boston, MA
Joined April 2015
Happy to report that we have identified secondary PIK3CA mutations as a novel mechanism of resistance to orthosteric PI3Kα inhibitors in breast cancer patients! @CD_AACR @MGHCancerCenter @harvardmed #CorcoranLab #Alpelisib #Inavolisib #bcsm.
1
9
28
RT @Aiims1742: An #OpenAccess review in @Cancer_Cell on circulating tumor cells (CTCs) from the prolific @MGHCancerCenter group:.Circulatin….
cell.com
Circulating tumor cells (CTCs) are cancer cells shed into the bloodstream. While their utility has been limited by challenges in rare cell capture, recent technological advances could enhance the...
0
11
0
RT @Cancer_Cell: Online Now: TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak https….
0
14
0
Very interesting letter to the editor complementing our study published early this year in @Annals_Oncology comparing established resistance mechanisms to KRASG12C-i and the newly reported #daraxonrasib (pan-RAS inhibitor) resistance patters in PDAC @VHIO .
0
2
9
RT @OncLive: RLY-2608 plus fulvestrant displayed a tolerable safety profile and preliminary activity in patients with PIK3CA-mutated, HR+/H….
onclive.com
Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.
0
8
0
First human genome from ancient Egypt sequenced from 4,800-year-old teeth 🤯🤯🤯.
nature.com
Nature - Whole-genome sequencing of an ancient male Egyptian revealed a mixture of North African Neolithic and eastern Fertile Crescent ancestry, suggesting human migration between Egypt and...
0
0
1
RT @NatureAging: 🗞️Our June issue is live!📷 This month, we're featuring work on editing epigenetic age, somatic mutation, senescence, Alzhe….
0
65
0
RT @hospitalclinic: 🗣️ “Les cremades solars a la infància són el càncer del futur”. Pel Dia Europeu de la Prevenció del #CàncerDePell recor….
0
6
0
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction! 🤯🤯🤯 @ScienceMagazine.
science.org
BBO-10203 is an orally available drug that covalently and specifically binds to the rat sarcoma (RAS)–binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS,...
0
0
1
RT @MGBResearchNews: In a new study, researchers from @MGHCancerCenter and colleagues found a new drug combo increased overall survival in….
0
1
0